ALFA Finder| Revenue growth | 30% Y-o-Y for Q4FY26; 11% Y-o-Y for full year FY26. |
|---|---|
| Margins | EBITDA margin at 2.28%, impacted by low-margin initial API sales. |
| Demand visibility | Stability expected in capsule business; API volumes to grow gradually. |
| Management confidence | High; confident in restoring growth and profitability in FY27. |
Growth
Revenue grew 30% Y-o-Y to ₹58.45 Cr; FY26 revenue reached ₹187.20 Cr, up 11% Y-o-Y. Standalone capsule sales boosted by ₹6 Cr deferred revenue.
Outlook
Commissioned new HPMC line for US markets; API commercial production started March 2026. Expects ₹67 Cr PLI incentive over 6 years.
Risks
Y-o-Y EBITDA dropped 70%; PAT and EPS saw significant losses due to operational stabilization costs and API segment ramp-up.
Earnings Call filed with BSE, NSE: NATCAPSUQ. Summary written with AI assistance from the document.
Natural Capsules Ltd: key numbers
- Share price
- ₹152.13
- Market cap
- ₹158.4 Cr
- Revenue (annual)
- ₹187.2 Cr
- Net profit (annual)
- ₹-24.66 Cr
- P/E (TTM)
- -7.4×Sector 43.7×
- Promoter holding
- 50.92%+0.00% QoQ
- FII holding
- 0.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natural Capsules Ltd
All →Natural Capsules Preferential Issue
Natural Capsules allotted 1,12,500 equity shares to a single investor at Rs.178 each on a preferential basis. The allotment is worth about Rs.2.00 Crore.
- Value
- ₹2.00 Cr
Natural Capsules Legal & Regulatory
Natural Capsules was fined ₹10,000 each by NSE and BSE for short board-meeting notice. The company has paid the fines and cited a late valuation report.
- Value
- ₹0.00 Cr
Natural Capsules Q2 FY27 Results: Net Loss of ₹4.2 Cr, Loss Narrows
Natural Capsules Ltd reported revenue from operations of ₹51.1 Cr (+11.6% YoY) and a net loss of ₹4.2 Cr for Q2 FY27.
- Key figure
- Net loss ₹4.2 Cr
Natural Capsules Preferential Issue
Natural Capsules added an allotment of 1,12,500 equity shares and 4,50,000 warrants to promoter Sunil Mundra to its 13 November board agenda. No issue price is stated.
Natural Capsules Board Meeting Date
Natural Capsules Limited has given prior intimation of a board meeting on 13 Nov 2026 to consider unaudited standalone and consolidated quarterly financial results for the period ended September 2026. The trading window closes from 01 Oct 2026 to 15 Nov 2026.
Natural Capsules Preferential Issue
Natural Capsules clarifies the object of its ₹10.01 Crore preferential issue of shares and warrants. Proceeds fund working capital and capital expansion.
- Value
- ₹10.01 Cr